La FDA déclare le CBD illégal

La FDA déclare le CBD illégal et prévient les agris tandis que la culture de chanvre vient d'être re-légalisée partout aux USA.

https://www.psychoactif.org/forum/2018/ … .html#divx

Cette décision tend à donner le monopole aux entreprises pharma qui utilisent des synthétiques.
Comme prévu, malheureusement, le marché se structure au profit de big pharma.

https://www.fda.gov/NewsEvents/Newsroom … 628988.htm

GW has been researching cannabinoids since 1998 and has established a world leading position in the development of plant-derived cannabinoid therapeutics through our proven drug discovery and development processes, our intellectual property portfolio and our regulatory and manufacturing expertise. GW’s research explores the potential therapeutic application of cannabinoids and we have evaluated the pharmacology of a number of cannabinoids across a wide range of disease areas.

Our primary focus is on disorders of the central nervous system (CNS), including epilepsy. Our lead cannabinoid product is a liquid formulation of highly purified plant-derived cannabidiol, or CBD, (Epidiolex® in the United States). In June 2018, the FDA approved Epidiolex for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome, two rare and particularly difficult to treat forms of epilepsy. The product was launched in November 2018 and is now available by prescriptions in the U.S.

We commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States. GW is in the process of working with the FDA to identify the optimal path to NDA submission for Sativex in the U.S.

We have a deep pipeline of additional cannabinoid product candidates which include compounds in development for epilepsy, autism spectrum disorders, glioma and schizophrenia.

GW is in a unique position to develop and manufacture plant-derived cannabinoid formulations worldwide at sufficient quality, uniformity and scale for the purposes of pharmaceutical development and to meet international regulatory requirements.

https://www.gwpharm.com/healthcare-professionals

Bayer/Monsanto reprennent l'avantage. (gw pharma est la "phytodivision" de bayer)

Dernière modification par Mister No (31 décembre 2018 à  11:34)